MARKET

ORXOY

ORXOY

Orexo Ab
OTCQX
1.910
NaN%
Closed 09:30 06/05 EDT
OPEN
--
PREV CLOSE
1.910
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
4.050
52 WEEK LOW
1.720
MARKET CAP
--
P/E (TTM)
0.716
1D
5D
1M
3M
1Y
5Y
1D
OREXO AB - SINGLE NASAL DOSE OF OX390 ACHIEVES TARGETED THERAPEUTIC EXPOSURE
Reuters · 05/19 12:58
Orexo reports positive in-vivo study data for OX390 nasal atipamezole absorption
PUBT · 05/19 06:07
Orexo AGM re-elects Friedrich von Bohlen und Halbach as board chair
PUBT · 05/07 15:03
Orexo publishes transcript of Q1 2026 earnings call
PUBT · 04/28 12:50
Orexo Q1 operating loss narrows to SEK 75 million; net sales fall to SEK 5 million
PUBT · 04/28 05:05
Orexo to host Q1 interim report presentation and Q&A session
PUBT · 04/21 08:01
Orexo says total shares 37.2 million, total voting rights 35.3 million
Reuters · 04/01 02:00
Orexo announces annual general meeting notice to shareholders
Reuters · 03/30 10:03
More
About ORXOY
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Webull offers Orexo AB - ADR stock information, including OTCQX: ORXOY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORXOY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORXOY stock methods without spending real money on the virtual paper trading platform.